WO2003097590A1 - Method for producing bicalutamide - Google Patents
Method for producing bicalutamide Download PDFInfo
- Publication number
- WO2003097590A1 WO2003097590A1 PCT/EP2003/004999 EP0304999W WO03097590A1 WO 2003097590 A1 WO2003097590 A1 WO 2003097590A1 EP 0304999 W EP0304999 W EP 0304999W WO 03097590 A1 WO03097590 A1 WO 03097590A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bicalutamide
- fluorophenyl
- formula
- radical
- precursor
- Prior art date
Links
- FHKLGEQKLMMVCZ-UHFFFAOYSA-N CC(Nc(cc1)cc(C(F)(F)F)c1C#N)=O Chemical compound CC(Nc(cc1)cc(C(F)(F)F)c1C#N)=O FHKLGEQKLMMVCZ-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
Definitions
- the present invention relates to a process for the preparation of ( ⁇ ) -N- (4'-cyano-3'-trifluoromethyl) -3- (4 "-fluorophenylsulfonyl) -2-hydroxy-2-methyl-propionamide and its R- ( -) - and S - (+) - enantiomers.
- N- (4'-Cyano-3'-trifluoromethyl) -3- (4 "-fluorophenylsulfonyl) -2-hydroxy-2-methyl-propionamide is also known under the INN name bicalutamide and belongs to the class of acylanilides.
- Bicalutamide has the following chemical structural formula:
- the compound has an asymmetric carbon atom (*) and can therefore occur both in its racemic form as ( ⁇ ) bicalutamide and as an R - (-) - or S - (+) - enantiomer.
- acylanilides have antiandrogenic properties and are now called nonsteroidal, peripheral antiandrogens. These compounds are for the therapy of androgen-related diseases, such as e.g. benign or malignant diseases of the prostate, hirsutism, acne etc. are suitable.
- Bicalutamide has been marketed in the form of its racemate under the trade name Casodex ® since 1995 as an agent for prostate cancer.
- a first synthetic route starting from methyl methacrylate, an epoxide is first prepared that is opened with p-FIuorthiophenol with addition. After an ester cleavage, the corresponding amide is formed and in the last step the sulfide is oxidized to the sulfone using a peracid such as m-chloroperbenzoic acid (m-CPBA).
- m-CPBA m-chloroperbenzoic acid
- WO 01/28990 discloses a process for the asymmetric synthesis of an enantiomer of an acylanilide by opening a ring structure.
- bicalutamide is described by reaction with p-fluorothiophenol and subsequent oxidation of the sulfide obtained to the corresponding sulfone using m-chloroperbenzoic acid.
- R is the respective remaining part of the bicalutamide framework or a corresponding precursor and X is either a common leaving group, such as e.g. Cl, Br, I, MesO, TosO, etc. or together with the ⁇ -carbon atom forms a corresponding epoxide, which then adds p-FIuorthiophenol to a sulfide under basic conditions, which is then oxidized to the corresponding sulfone in the next step.
- this reaction sequence does not have to occur at the end of a bicalutamide synthesis, but can also be used in the middle of the reaction sequence.
- the oxidation does not necessarily have to follow the formation of the sulfide immediately, but can also be carried out later. However, both individual steps are used in all bicalutamide syntheses.
- p-FIuorthiophenol is a toxic and highly irritating material that requires appropriate precautions to be able to use this compound on an industrial scale.
- p-fluorothiophenol is difficult to obtain in isomerically pure form. Appropriate purification is complex.
- a strong base is required for the addition of p-fluorothiophenol.
- Most synthesis processes use sodium hydride, which, however, makes the use of absolute solvents necessary and which complicates the reaction on an industrial scale due to the very high sensitivity to hydrolysis.
- bicalutamide which preferably provides the bicalutamide either in racemic or in enantiomerically pure form.
- the bicalutamide should, if possible, be obtained in the purity necessary for use in medicinal products.
- the present invention thus relates to a process for the preparation of bicalutamide, in which an epoxide of the general formula (I)
- R is a radical of the formula (II)
- an epoxy precursor namely a compound of the general formula (III)
- an epoxy precursor namely a compound of the general formula (III)
- R is as defined above and X is a leaving group.
- the method according to the invention thus avoids the use of the toxic p-fluorothiophenol and the need for an oxidation step through the use a p-fluorophenyl sulfinate as an epoxy-opening reagent.
- a p-fluorophenyl sulfinate as an epoxy-opening reagent.
- the desired product bicalutamide or a precursor thereof which already contains the desired sulfone group is obtained directly.
- the epoxide of the general formula (I) can either be used as a starting material in the process according to the invention or by a ring closure reaction from a compound of the general formula (III)
- the epoxy obtained as an intermediate can be isolated and purified, but the reaction is preferably continued as a one-pot reaction without isolation of the epoxide. This reduces the time and effort and thus the synthesis costs and still enables the desired bicalutamide to be obtained in sufficient purity.
- the compound of the general formula (III) can be reacted directly with the p-fluorophenyl sulfinate salt without intermediate oxirane formation.
- the epoxide used or its open-chain precursor is preferably selected so that the desired bicalutamide is obtained directly when reacting with the p-fluorophenyl sulfinate.
- R in the general formulas (I) and (III) represents a radical of the formula (II)
- R in general formulas (1) and (III) can also be chosen so that the product obtained in the reaction from the epoxy with the p-fluorophenyl sulfinate salt is suitable as a precursor for the further synthesis of bicalutamide.
- R is selected such that R is used as a precursor for a radical of the formula (II)
- a suitable precursor for a radical of the formula (II) is, for example, the radical -COY where Y is a group suitable for the subsequent amide formation.
- the intermediate product obtained in the reaction of the epoxide with the p-fluorophenyl sulfinate salt can easily be further reacted with 3-trifluoromethyl-4-cyanoaniline to give the desired bicalutamide.
- Particularly suitable precursors for a radical of the formula (II) are carboxyl, acid halides such as acid chloride, normal esters and activated esters. Suitable radicals are known to the person skilled in the art and can be selected in accordance with the reaction procedure. If in the process according to the invention not from an epoxide of the general formula (I) but from a precursor thereof, namely a compound of the general formula (III)
- the leaving group X can be selected by the person skilled in the art in accordance with the chosen reaction conditions. Suitable leaving groups are known to those skilled in the art and include halogens such as e.g. Cl, Br and I, as well as reactive leaving groups such as Alkali and aryl sulfonates and especially mesylate, tosylate and brosylate.
- halogens such as e.g. Cl, Br and I
- reactive leaving groups such as Alkali and aryl sulfonates and especially mesylate, tosylate and brosylate.
- Suitable starting materials in which X is a halogen are e.g. already known from WO 98/55153 or can be easily prepared from the epoxy precursor using conventional organic chemistry processes.
- Suitable starting materials in which X is a common leaving group such as is a mesylate, brosylate or tosylate group are known from WO 01/00608 and can be obtained from the corresponding alcohol precursor by means of conventional organic chemistry processes.
- the p-fluorophenyl sulfinate salts used according to the invention are preferably ammonium p-fluorophenyl sulfinate, alkaline earth p-fluorophenyl sulfinates or alkali p-fluorophenyl sulfinates and particularly preferably sodium p-fluorophenyl sulfinate. This can be done in a known way, for example to Olah, Paviath, Acta Chim. Hung. 4 [1954] pp. 111-117, can be obtained in very good yield.
- the method according to the invention also has the advantage that the opening of the epoxide does not influence the sterochemical center already present in the epoxy, so that the method according to the invention both for the preparation of the (+) - bicalutamide and for the preparation of the R - (-) - or the S - (+) - bicalutamide can be used.
- the only thing that matters here is whether the racemic epoxide or its halohydrin precursor or a corresponding optically active R or S epoxide or the corresponding optically active halohydrin precursor is used as a starting material.
- the inventive reaction of the epoxide with the p-fluorophenyl sulfinate salt is preferably carried out in a suitable solvent, such as e.g. Methanol or DMF, in the presence of an acid such as e.g. Glacial acetic acid, at room temperature or with heating.
- a suitable solvent such as e.g. Methanol or DMF
- an acid such as e.g. Glacial acetic acid
- the epoxide of the general formula (I) is reacted with sodium p-fluorophenyl sulfinate for about 5 hours in a suitable solvent such as methanol after the addition of glacial acetic acid with heating to about 50 ° C.
- a suitable solvent such as methanol
- the reaction mixture is worked up by removing the volatile constituents by an aqueous-organic extraction process.
- the crude product obtained after stripping off the organic solvent is recrystallized from a suitable solvent, for example from diisopropyl ether, to give pure bicalutamide. This reaction is illustrated by the reaction scheme below:
- the corresponding oxirane is first generated in situ from an open-chain compound of the general formula (IN) (for example by heating the compound of the general formula (III) with potassium tert-butoxide in toluene).
- this is then treated with sodium p-fluorophenyl sulfinate in a suitable solvent, such as e.g. Dimethylformamide (DMF), after adding glacial acetic acid at room temperature or slightly elevated temperature for about 16 h to react.
- a suitable solvent such as e.g. Dimethylformamide (DMF)
- the yield of bicalutamide is naturally better than with an intermediate isolation of the oxirane due to the fact that it is conducted as a one-pot reaction, since, for example, a normal workup loss is avoided when isolating the oxirane.
- the reaction residue can be worked up for example, after removing volatile constituents in dimethylformamide and diluted with water, the product crystallizing out. If necessary, further purification by recrystallization from a suitable solvent, such as diisopropyl ether, can follow.
- reaction mixture is evaporated to dryness and the residue is taken up in 50 ml of CH 2 Cl 2 and 20 ml of water.
- organic phase is washed several times with water and dried over MgS0. After the solvent has been stripped off, crude bicalutamide is obtained, which is recrystallized from diisopropyl ether for further purification.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002468426A CA2468426A1 (en) | 2002-05-17 | 2003-05-13 | Process for preparing n-(4'-cyano-3'-trifluoromethylphenyl)-3-(4"-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide |
US10/498,862 US7323584B2 (en) | 2002-05-17 | 2003-05-13 | Process for preparing N-(4′-cyano-3′-trifluoromethylphenyl)-3-(4″-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide |
EP03730023A EP1506170B1 (en) | 2002-05-17 | 2003-05-13 | Method for producing bicalutamide |
DE50309260T DE50309260D1 (en) | 2002-05-17 | 2003-05-13 | PROCESS FOR THE PREPARATION OF BICALUTAMIDE |
JP2004505323A JP2005530795A (en) | 2002-05-17 | 2003-05-13 | Method for producing bicalutamide |
AU2003240634A AU2003240634A1 (en) | 2002-05-17 | 2003-05-13 | Method for producing bicalutamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10222104A DE10222104A1 (en) | 2002-05-17 | 2002-05-17 | Process for the preparation of N- (4'-cyano-3'-trifluoromethyl) -3- (4 "-fluorophenylsulfonyl) -2-hydroxy-2-methylpropionamide |
DE10222104.9 | 2002-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003097590A1 true WO2003097590A1 (en) | 2003-11-27 |
Family
ID=29413932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004999 WO2003097590A1 (en) | 2002-05-17 | 2003-05-13 | Method for producing bicalutamide |
Country Status (10)
Country | Link |
---|---|
US (1) | US7323584B2 (en) |
EP (1) | EP1506170B1 (en) |
JP (1) | JP2005530795A (en) |
AT (1) | ATE387425T1 (en) |
AU (1) | AU2003240634A1 (en) |
CA (1) | CA2468426A1 (en) |
DE (2) | DE10222104A1 (en) |
ES (1) | ES2299700T3 (en) |
PT (1) | PT1506170E (en) |
WO (1) | WO2003097590A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031136A1 (en) * | 2002-10-02 | 2004-04-15 | Synthon B.V. | Process for making bicalutamide and intermediates thereof |
WO2005009946A1 (en) * | 2003-06-25 | 2005-02-03 | TEVA Gyógyszergyár Részvénytársaság | Process for purifying and isolating rac-bicalutamide |
US7102026B2 (en) | 2001-06-13 | 2006-09-05 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Process for preparing and isolating rac-bicalutamide and its intermediates |
US7785629B2 (en) | 2005-06-21 | 2010-08-31 | Helm Ag | Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060159767A1 (en) * | 2004-12-22 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate bicalutamide formulations |
US20080177109A1 (en) * | 2005-03-29 | 2008-07-24 | Usv Limited | Novel Process for Preparation of Bicalutamide |
CA2513356A1 (en) * | 2005-07-26 | 2007-01-26 | Apotex Pharmachem Inc. | Process for production of bicalutamide |
CZ299577B6 (en) * | 2005-12-20 | 2008-09-03 | Interpharma Praha, A. S. | Process for preparing extremely pure 4-cyano-3-trifluoromethyl-N-( 3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl) aniline |
CN106748884B (en) * | 2016-12-13 | 2021-08-20 | 山西振东制药股份有限公司 | Preparation method of bicalutamide intermediate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3304054A1 (en) * | 1983-02-07 | 1984-08-09 | Henkel KGaA, 4000 Düsseldorf | 2-Alkyl- or arylsulphonyl-2,2-dibromoacetamides and their use as antimicrobial active compounds |
WO2001000608A1 (en) * | 1999-06-10 | 2001-01-04 | Richter Gedeon Vegyészeti Gyár Rt. | Process for the synthesis of n-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide |
WO2001028990A2 (en) * | 1999-10-19 | 2001-04-26 | Nobex Corporation | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof |
US20030073742A1 (en) * | 2002-10-02 | 2003-04-17 | Synthon B.V. | Process for making bicalutamide and intermediates thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3700729A1 (en) * | 1987-01-13 | 1988-07-21 | Boehringer Mannheim Gmbh | NEW CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE4105743C1 (en) * | 1991-02-23 | 1992-10-01 | Merck Patent Gmbh, 6100 Darmstadt, De | Benzyl:aryl:sulphone(s) useful as LCD - are produced by reacting salt of aryl:sulphinic acid with corresp. benzyl halide |
-
2002
- 2002-05-17 DE DE10222104A patent/DE10222104A1/en not_active Withdrawn
-
2003
- 2003-05-13 US US10/498,862 patent/US7323584B2/en not_active Expired - Fee Related
- 2003-05-13 AT AT03730023T patent/ATE387425T1/en not_active IP Right Cessation
- 2003-05-13 CA CA002468426A patent/CA2468426A1/en not_active Abandoned
- 2003-05-13 PT PT03730023T patent/PT1506170E/en unknown
- 2003-05-13 ES ES03730023T patent/ES2299700T3/en not_active Expired - Lifetime
- 2003-05-13 EP EP03730023A patent/EP1506170B1/en not_active Expired - Lifetime
- 2003-05-13 WO PCT/EP2003/004999 patent/WO2003097590A1/en active IP Right Grant
- 2003-05-13 AU AU2003240634A patent/AU2003240634A1/en not_active Abandoned
- 2003-05-13 JP JP2004505323A patent/JP2005530795A/en active Pending
- 2003-05-13 DE DE50309260T patent/DE50309260D1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3304054A1 (en) * | 1983-02-07 | 1984-08-09 | Henkel KGaA, 4000 Düsseldorf | 2-Alkyl- or arylsulphonyl-2,2-dibromoacetamides and their use as antimicrobial active compounds |
WO2001000608A1 (en) * | 1999-06-10 | 2001-01-04 | Richter Gedeon Vegyészeti Gyár Rt. | Process for the synthesis of n-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide |
WO2001028990A2 (en) * | 1999-10-19 | 2001-04-26 | Nobex Corporation | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof |
US20030073742A1 (en) * | 2002-10-02 | 2003-04-17 | Synthon B.V. | Process for making bicalutamide and intermediates thereof |
Non-Patent Citations (2)
Title |
---|
CULVENOR, C.C.J. ET AL., J. CHEM. SOC., 1949, pages 2198 - 2206, XP001091304 * |
KLAMANN, D. (ED.): "Methoden der organischen Chemie (Houben-Weyl), Band E11 Organische Schwefel-Verbindungen", 1985, GEORG THIEME VERLAG, STUTTGART, XP002253733 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7102026B2 (en) | 2001-06-13 | 2006-09-05 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Process for preparing and isolating rac-bicalutamide and its intermediates |
WO2004031136A1 (en) * | 2002-10-02 | 2004-04-15 | Synthon B.V. | Process for making bicalutamide and intermediates thereof |
US7186854B2 (en) | 2002-10-02 | 2007-03-06 | Synthon Ip Inc. | Process for making bicalutamide and intermediates thereof |
WO2005009946A1 (en) * | 2003-06-25 | 2005-02-03 | TEVA Gyógyszergyár Részvénytársaság | Process for purifying and isolating rac-bicalutamide |
US7785629B2 (en) | 2005-06-21 | 2010-08-31 | Helm Ag | Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2005530795A (en) | 2005-10-13 |
US7323584B2 (en) | 2008-01-29 |
ES2299700T3 (en) | 2008-06-01 |
DE50309260D1 (en) | 2008-04-10 |
AU2003240634A8 (en) | 2003-12-02 |
AU2003240634A1 (en) | 2003-12-02 |
EP1506170B1 (en) | 2008-02-27 |
PT1506170E (en) | 2008-04-07 |
EP1506170A1 (en) | 2005-02-16 |
DE10222104A1 (en) | 2003-12-04 |
US20050033082A1 (en) | 2005-02-10 |
CA2468426A1 (en) | 2003-11-27 |
ATE387425T1 (en) | 2008-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1678119B1 (en) | Method for producing 2-dihaloacyl-3-amino-acrylic acid esters and 3-dihalomethyl-pyrazole-4-carboxylic acid esters | |
DE69534190T2 (en) | Process for the preparation of 1,2-benzisothiazol-3-ones | |
EP0124009A2 (en) | Process for the preparation of oxiranes | |
DE19961603A1 (en) | Production of 2-chlorocyclopropyl-1-chlorophenyl-triazolonyl-propanol derivative, useful as microbicide, from 2-chlorocyclopropyl-2-chlorobenzyl-oxirane | |
DE102005061720B3 (en) | Preparing optically active omeprazole enantiomers, useful to treat stomach diseases, comprises oxidizing prochiral sulfide compound with oxidizing agent in presence of titanium complex catalyst and reacting the catalyst with chiral diols | |
EP1506170B1 (en) | Method for producing bicalutamide | |
EP0918744B1 (en) | Racemic separation of ketamine | |
DE60105441T2 (en) | PROCESS FOR PREPARING PANTOPRAZOLE AND INTERMEDIATE PRODUCTS OF THIS METHOD | |
EP0298020B1 (en) | Use of an epoxidation reagent, and process for the preparation of 5-alpha (10-alpha) epoxy-delta 9(11) steroids | |
DE3730748A1 (en) | NEW POLYOXYGENATED LABDANE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT | |
EP0008057A1 (en) | Process for the preparation of N-substituted alpha-haloacetanilides | |
DE3315510A1 (en) | METHOD FOR PRODUCING OXIRANES | |
DE602004007997T2 (en) | Process for the preparation of pantoprazole and its salts | |
DE3315524A1 (en) | METHOD FOR PRODUCING OXIRANES | |
EP0236884B1 (en) | Method for the preparation of phenoxyalkanoltriazole compounds, and intermediates therefor | |
EP0001089A1 (en) | Process for the preparation of halogenovinyl-substituted 2-tetrahydrofuranones, selected halogenovinyl-substituted 2-tetrahydrofuranones | |
WO1994002443A2 (en) | PROCESS FOR PREPARING ENANTIOMER-PURE β-SUBSTITUTED η-AMINOBUTYRIC ACID DERIVATES, NEW ENANTIOMER-PURE INTERMEDIATE STAGES OF SAID PROCESS AND THEIR USE | |
EP0277572A2 (en) | Process for the preparation of optically active 2-hydroxyethyl-azole derivatives | |
DE69333903T2 (en) | Optically active 1-phenylpyrrolidone derivatives | |
DE2628469B2 (en) | Process for the preparation of γ-amino alcohols | |
WO2015055293A1 (en) | Method for the preparation of 1,2-benzisothiazolin-3-ones | |
EP0150411A1 (en) | Process for the preparation of substituted quinazoline-2,4(1H,3H)-diones | |
DE3722278A1 (en) | Process for the preparation of 1-[3'-{bromo}-(2'S)-{methyl}-propionyl]-pyrrolidine-(2S)-carboxylic acid or its monohydrate | |
DE952715C (en) | Process for the production of new antihistamine effective basic AE ethers | |
DE3425138A1 (en) | Process for the preparation of an optically active phenoxypropionic ester derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2468426 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003730023 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10498862 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004505323 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003730023 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003730023 Country of ref document: EP |